Publication date: Oct 14, 2024
We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal SARS-CoV-2 PCR at study days 3, 7, 14, and 28. Viral rebound was defined as RNA ≥3 and ≥0. 5 log10 copies/mL increase from day 3 or 7, and symptom rebound as hospitalization or any moderate/severe symptom for ≥2 days after initial symptom improvement. There was no difference in viral rebound (∼5%/arm) (analysis population n=713) or symptom rebound among participants who initially improved (hazard ratio 0. 95 (95% CI 0. 52, 1. 75, analysis population) n=574);
| Concepts | Keywords |
|---|---|
| A5401 | COVID-19 |
| Covid | COVID-19 treatment |
| Hospitalization | monoclonal antibodies |
| Pcr | non-hospitalized adults |
| Viral | SARS-CoV-2 |
| symptom rebound | |
| viral rebound |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | symptom |
| disease | MESH | COVID-19 |
Original Article
(Visited 3 times, 1 visits today)